Cardiovascular outcomes after hematopoietic stem cell transplantation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter observational cohort of patients who received hematopoietic cell transplantation at participating centers. Investigators will enroll transplant recipients and collect clinical characteristics, laboratory profiles, management measures, and follow-up data on cardiovascular events. Data will be gathered prospectively across several major tertiary hospitals and pooled for analysis of incidence and risk factors. The aim is to characterize post-transplant cardiovascular outcomes and drivers of risk to inform future care strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who undergo hematopoietic cell transplantation at any of the participating medical centers.

Exclusion Criteria:

* Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.
* Patient request to withdraw from the study.

Where it's running

• Chinese PLA General Hospital
  Beijing, Beijing Municipality, China Recruiting
• Peking University First Hospital
  Beijing, Beijing Municipality, China Recruiting
• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting
• Peking University Third Hospital
  Beijing, Beijing Municipality, China Recruiting
• Xinqiao hospital of the third military medical university
  Chongqing, Chongqing Municipality, China Recruiting
• Sun Yat-sen University Cancer Center, Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Xiao Hui Zhang
• Email: zhangxh@bjmu.edu.cn
• Phone: 861088324577

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Population PK-guided ATG Dosing in Haploidentical Stem Cell Transplant

  This trial tests a population PK-guided ATG dosing strategy in people undergoing haploidentical hematopoietic stem cell transplantation to see if it improves outcomes.

  Recruiting Phase 3 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07862127

• Population PK-guided ATG Dosing in Haplo-HSCT

  This study tests a population PK-guided dosing strategy for anti-thymocyte globulin (ATG) in adults and adolescents undergoing haploidentical stem cell transplantation to see if it can reduce GVHD while keeping relapse risk acceptable.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07791576

• Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children

  This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Haikou, Hainan · NCT07725263

• Personalized ATG dosing in unrelated donor stem cell transplants

  This trial tests whether tailoring anti-thymocyte globulin dosing works better than standard fixed dosing in adults and adolescents receiving unrelated donor stem cell transplants.

  Recruiting Phase 4 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07648992

• Hematologic cancer survivors after stem cell transplant try a personalized care plan

  This study tests a personalized Survivorship Care Plan for people with hematologic cancer who have undergone a stem cell transplant to see if it’s feasible within the Italian health system.

  Recruiting Azienda USL Reggio Emilia - IRCCS · Reggio Emilia · NCT07579065

• T-cell–guided letermovir stopping after allogeneic stem cell transplant

  This tests whether using a CMV-specific T-cell blood test to decide when adult CMV-positive patients can stop letermovir after allogeneic stem cell transplant keeps them protected while avoiding unnecessary drug exposure.

  Recruiting Phase 4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Beijing, Beijing Municipality and 11 other locations · NCT07569653

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.